CD274 and neoplasm: Vactosertib (50 mg/kg p.o. 5 days/week) was administrated 3 weeks later with or without weekly ICB administration (α-PD-1 or α-PD-L1 mAb, 100ug/mouse/week, i.p.), and OS tumor burden was monitored by BLI (Figure 9A).